New drug combo for rare blood cancer shows early promise, but trial halted
NCT ID NCT05083208
First seen Dec 29, 2025 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-phase trial tested a combination of two drugs (parsaclisib and chidamide) in 12 people with a rare type of blood cancer called peripheral T-cell lymphoma that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.